Skip to main content
Premium Trial:

Request an Annual Quote

CSI Laboratories PD-L1 Expression Assay

CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, has launched a PD-L1 (programmed death-ligand 1) immunohistochemical protein expression assay, which can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies. More specifically, the assay provides a specimen's PD-L1 tumor cell reactivity score, which can be used to identify patients who are more likely to respond to certain PD-1/PD-L1 inhibitor therapies.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more